Neos Therapeutics, Inc. (NEOS) Now Covered by Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald initiated coverage on shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) in a report released on Monday, July 31st, MarketBeat Ratings reports. The firm set an “overweight” rating and a $20.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 200.75% from the company’s previous close. Cantor Fitzgerald also issued estimates for Neos Therapeutics’ FY2017 earnings at ($3.00) EPS and FY2018 earnings at ($1.47) EPS.

Several other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. ValuEngine downgraded shares of Neos Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 27th. Cowen and Company assumed coverage on shares of Neos Therapeutics in a research report on Wednesday, April 5th. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price objective on shares of Neos Therapeutics in a research report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $14.00.

Shares of Neos Therapeutics (NEOS) traded down 0.75% during trading on Monday, hitting $6.65. 265,651 shares of the stock traded hands. The firm’s market cap is $186.73 million. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $9.60. The company has a 50 day moving average price of $6.90 and a 200 day moving average price of $7.00.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Tuesday, August 8th. The company reported ($0.83) EPS for the quarter, hitting the consensus estimate of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The firm had revenue of $4.91 million for the quarter. Analysts anticipate that Neos Therapeutics will post ($3.20) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/08/19/cantor-fitzgerald-initiates-coverage-on-neos-therapeutics-inc-neos-updated-updated.html.

Several hedge funds and other institutional investors have recently bought and sold shares of NEOS. TIAA CREF Investment Management LLC boosted its position in shares of Neos Therapeutics by 4.9% in the second quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock valued at $342,000 after buying an additional 2,168 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after buying an additional 2,441 shares during the last quarter. Falcon Point Capital LLC boosted its position in shares of Neos Therapeutics by 3.1% in the first quarter. Falcon Point Capital LLC now owns 88,279 shares of the company’s stock valued at $636,000 after buying an additional 2,691 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Neos Therapeutics by 13.0% in the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock valued at $396,000 after buying an additional 6,223 shares during the last quarter. Hedge funds and other institutional investors own 35.38% of the company’s stock.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

What are top analysts saying about Neos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neos Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit